Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

118.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?
Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17. 
Via Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. 
Via StockStory
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
These 2 Dividend Stocks Are Absolute Bargains Right Now
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
 
Via Benzinga
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
 
Via Benzinga
Top Analyst Reports For Uber, Comcast & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc., Comcast Corp, and Gilead Sciences, Inc., as well as a micro-cap stock Onfolio Holdings, Inc. 
Via Talk Markets
Topics Stocks / Equities
3 Top AI-Powered Biotech Stocks to Buy in February
Via The Motley Fool
Salesforce Names Board Member As Software Maker's New CFO And COO
The Dow software giant named Robin Washington, as its new CFO and COO. 
Via Investor's Business Daily
Topics Stocks
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
 
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Gilead Sciences, Inc.
Via Business Wire
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena. 
Via Stocktwits
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
From Gilead Sciences, Inc.
Via Business Wire
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline. 
Via Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
Healthcare And Biotech Stocks Continue Their Slide
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout.
GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.